Castle Biosciences' TissueCypher Test Alters Management in 90% of…

Event summary

Castle Biosciences' TissueCypher test changed management recommendations for 90% of patients with non-dysplastic Barrett's esophagus (NDBE) in a study at Keck Medicine of USC.
The test identified 17% of patients as intermediate or high risk, leading to escalated management for all of them.
For 84% of low-risk patients, management was de-escalated, including extending surveillance intervals.
The study was published in Foregut: The Journal of the American Foregut Society and presented at the American College of Surgeons Clinical Congress 2026.

The big picture

Castle Biosciences' TissueCypher test demonstrates the potential to significantly impact the management of Barrett's esophagus, a precancerous condition affecting a large patient population. The study highlights the need for more precise risk stratification tools in gastroenterology, as traditional methods often fail to distinguish high-risk patients. This development aligns with broader industry trends toward personalized medicine and AI-driven diagnostics, which aim to improve patient outcomes through tailored treatment plans.

What we're watching

Clinical Adoption: How quickly TissueCypher will be integrated into routine endoscopic practice and adopted by other expert surgery centers.
Regulatory Approval: Whether the positive study results will accelerate regulatory approvals or reimbursement discussions for TissueCypher.
Market Expansion: The pace at which Castle Biosciences can expand the use of TissueCypher to other high-risk patient populations beyond NDBE.